Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

The Outlook For Johnson & Johnson's Immunology Drug Business

Forbes - 5 Dec 2017 20:55
Johnson & Johnson's immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company's value, according to our estimates.
Full Article at Forbes

More Market News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard